- Home
- PACB vs KROS Comparison
PACB vs KROS Comparison
Compare PACB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PACB | KROS |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.5M | 655.9M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PACB | KROS |
|---|---|---|
| Price | $2.67 | $19.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $2.08 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 7.9M | 376.5K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $154,584,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $4.19 | $6,924.79 |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | ★ N/A | $12.37 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $0.85 | $9.12 |
| 52 Week High | $2.73 | $22.55 |
Technical Indicators
Market Signals| Indicator | PACB | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 49.43 |
| Support Level | $2.09 | $18.33 |
| Resistance Level | $2.22 | $19.67 |
| Average True Range (ATR) | 0.20 | 0.70 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 92.70 | 69.55 |
Price Performance
Historical ComparisonAbout PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.